Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing

被引：26
作者：
Baselga, J [1 ]
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷 / 01期
关键词：
D O I：
10.1093/annonc/mdf092
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：8 / 9
页数：2
相关论文
共 17 条
[1]  
ANIDO J, 2001, P AN M AM SOC CLIN, V20, pA1712
[2]  
Baselga J, 2001, J CLIN ONCOL, V19, p41S
[3]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[4]  
BONNER JA, 2000, P AN M AM SOC CLIN, V19, pF5
[5]  
Ciardiello F, 2000, CLIN CANCER RES, V6, P2053
[6]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[7]  
HARRIS AL, 1989, CANCER CEL, V7, P353
[8]  
MOULDER SL, 2001, P AN M AM SOC CLIN, V20, pA8
[9]   Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth [J].
Normanno, N ;
Campiglio, M ;
De Luca, A ;
Somenzi, G ;
Maiello, M ;
Ciardiello, F ;
Gianni, L ;
Salomon, DS ;
Menard, S .
ANNALS OF ONCOLOGY, 2002, 13 (01) :65-72
[10]   EPIDERMAL GROWTH FACTOR-RELATED PEPTIDES AND THEIR RECEPTORS IN HUMAN MALIGNANCIES [J].
SALOMON, DS ;
BRANDT, R ;
CIARDIELLO, F ;
NORMANNO, N .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1995, 19 (03) :183-232
12